HRT of Menopausal transition and early menopausal women



Sung Hoon Kim, M.D.

Dept. of Obstetrics & Gynecology University of Ulsan College of Medicine Asan Medical Center

Terminology

➢ Recommended by the WHO in 1996

Natural menopause

Permanent cessation of menstruation resulting from the loss of ovarian follicular activity

After 12 consecutive months of amenorrhea without no other obvious pathologic or physiologic cause

> Perimenopause :

Period immediately before the menopause and the first year after menopause.


STRAW Definition

Stages of Reproductive Aging Workshop (2001)


	Final Menstrual Period (FMP)								
Stages:	-5	-4	-3	-2	-1	+1	+2		
Terminology:	Reproductive				Menopausal Transition		Postmenopause		
	Early	Peak	Late	Early	Late*	Early	/* Late		
				Perim	enopause				
Duration of Stage:	variable		var	iable	ⓐ ⓑ 1 yr 4 y	demise			
Menstrual Cycles:	variable to regular	regular		variable cycle length (>7 days different from normal)	≥2 skipped cycles and an interval of amenorrhea (≥60 days)	Amen x 12 mos	none		
Endocrine:	normal FSH		↑ FSH ↑ FSH			↑FSH			



Importance of menopausal transition period



Timing hypothesis



HT initiated during perimenopausal transition or early menopause: slow the progression of lesions into larger, more complicated plaques. Beneficial effects of HT will be lost several years after menopause

HRT of Menopausal transition and early menopausal women

- > Endocrine change during perimenopausal period
- Management of Vasomotor symptom
- Management of DUB
- > Osteoporosis prevention
- ➤ When to start HT?

Endocrine Changes

Table 1. Stages of the Menopausal Transition, Ranges of Hormone Levels, and the Prevalence of Hot Flushes.


Variable	Reproductive Years			Menopausal Transition (Perimenopause)		Postmenopausal Years	
	Early	Peak	Late	Early	Late	Early	Late
Menstrual cycle	Regular or variable	Reg	ular	Variable cycle length; 1 or 2 missed cycles per yr	3 or more missed cycles per yr	No	one
Range of steroid hormones (pg/ml)							
Estradiol		50–200		50–200 or slig	htly higher;	40	0–15
Testosterone		400		400)	400	400
Range of pituitary hormones (mU/ml)							
Follicle-stimulating hormone	10	on days 2–4		10 or higher o	on days 2–4	>1	.00
Luteinizing hormone	10	on days 2–4		10 or higher o	on days 2–4	>1	.00
Prevalence of hot flushes (%)			10	40	65	50	10–15

Hot flush : prevalence increase through MT

Prevalence varies markedly among studies.



Endocrinology of late reproductive aging



F. J. Broekmans et al. Endocrine Reviews, August 2009, 30(5):465-493

Endocrinology of the menopausal transition

> Early menopausal transition:

: Profound fall in the follicular phase concentrations of inhibin B with FSH levels being slightly raised


:Cyclicity is for the most part preserved

: highly variable patterns of gonadotropin and sex steroid output

Endocrinology of the menopausal transition


- > Late menopausal transition :
 - : Marked falls in E2 and inhibin A together with significant elevations in FSH
- Follicle failure appears to occur, and sex steroid production wanes dramatically
- Eventually, menstrual cycles cease, but estrogen production occurs for a period of 6months to 2 years
 Steady state of hypergonadotropic hypogonadism

Clinical Issues in Perimenopause



Vasomotor Symptoms

Mechanisms not fully understood.
 Vasomotor dysfunction : frequency, severity increase during MT (OR; 1.3-13)





Clinical Significance of VMS ➢ QoL (Hot Flush, Night sweat …) ➢ Vascular endothelial dysfunction → CVD risk (2007, JAMA)

Table 6. Cardiovascular and Global Index Events in Subgroup of Participants with Moderate or Severe Vasomotor Symptoms at Baseline in the Combined Trials





Table 7. Cardiovascular and Global Index Events in Subgroup of Participants With Moderate or Severe Vasomotor Symptoms at Baseline in the Combined Trials



VMS & Depressive Symptoms

Table 2. Risk of First Onset of Depressive Symptoms in Premenopausal and Perimenopausal Women With No Lifetime History of Major Depression


At Outcome or End of Follow-up	Any First Onset, No. (%)	Adjusted OR (95% CI)*	Severe First Onset, No. (%)†	Adjusted OR (95% Cl)*
Premenopausal (n = 95)‡	19 (20.0)	1.0	9 (9.5)	1.0
Perimenopausal (n = 326)	106 (32.5)	1.8 (1.0-3.2)	54 (16.6)	1.9 (0.9-4.0)
No vasomotor symptoms (n = 169)§	52 (30.8)	1.8 (0.9-2.5)	23 (13.6)	1.6 (0.7-3.7)
Vasomotor symptoms (n = 135)	49 (36.3)	2.2 (1.1-4.2)	26 (19.3)	2.5 (1.1-5.8)
Unknown vasomotor symptoms (n = 22)	5 (22.7)	1.0 (0.3-3.3)	5 (22.7)	2.7 (0.8-9.1)
"Hormone-modulated" perimenopause (n = 49)	17 (34.7)	2.0 (0.9-4.5)	5 (10.2)	1.1 (0.4-3.7)
Natural perimenopause (n = 277)	89 (32.1)	1.8 (1.0-3.2)	49 (17.7)	2.0 (0.9-4.4)



 Table 2. Efficacy of Treatment of Hot Flushes with Various Doses of Estrogen, as Compared with Placebo.

Study Group	Reduction in Frequency of Hot Flushes percent*				
Oral conjugated equine estrogens (mg) ¹⁷					
0.625	94				
0.45	78				
0.30	78				
Placebo	44				
Oral 17β-estradiol (mg) ¹⁸					
2.0	96				
1.0	89				
0.5	79				
0.25	59				
Placebo	55				
Transdermal 17 β -estradiol (mg) ¹⁹					
0.1	96				
0.05	96				
0.025	86				
Placebo	45				

Deborah et al. N Engl J Med 2006;355:2338-47.



Bruce et al. The American Journal of Medicine (2005) Vol 118, 74S-78S

The Hot Flush				
Premenopausal	10–25% of women			
Perimenopausal	60%			
Postmenopausal:				
No flushes	15-25%			
Daily flushing	15-20%			
Duration	1–2 years average			
	5 or more years: 25%			
Other Causes	Psychosomatic			
	Stress			
	Thyroid disease			
	Subacute, chronic infections			
	Pheochromocytoma			
	Carcinoid			
	Leukemia			
	Cancer			

Estrogen deficiency as the cause of hot flushes should be documented by increased FSH.

Prescribing estrogen inappropriately in the presence of normal levels of gonadotropins only temporarily postpones dealing with the underlying issues by a placebo response

Wilkin JK.Ann Intern Med. 1981Oct;95(4):468-76

Little response to large doses of estrogen
 Careful inquiry for a basic psychoneurotic or psychosocial problem

Measuring the patient's blood level of estradiol and showing the result

 \rightarrow Help persuade a patient that her symptoms not due to low levels of estrogen

 The NAMS guideline 2004.
 Mild vasomotor symptoms: first consider lifestyle changes either alone or combined with a nonprescription remedy

Moderate to severe hot flushes:

HRT is recommended as the therapeutic standard. Progestins, SSRIs, or gabapentin -suggested as an alternative for avoiding estrogens Table 5. Evidence of the Efficacy of Nonestrogenic Prescription Drugs for the Treatment of Menopausal Hot Flushes from Randomized, Controlled Clinical Trials.*

Treatment	Oral Dose	Evidence of Benefit	Outcome†	Side Effects:
Nonestrogen hormon	les			
Progestins				
MPA	20 mg daily	Yes	Improvement of 48% over placebo ³⁰	Nausea, vomiting, constipation, somno-
Megestrol	20 mg twice daily	Yes	Improvement of 47% over placebo in breast cancer survivors ³¹	lence, depression, breast tenderness, and uterine bleeding; concern about increased risks of venous thrombo- embolism, cardiovascular events, and breast cancer
Tibolone§	1.25 to 5.0 mg	Yes	Improvement of 35–50% over placebo ^{4,32}	Headache, weight gain, and uterine bleed- ing; unknown effects on venous throm- boembolic events, cardiovascular dis- ease, and breast and uterine cancer
Antidepressants				
SSRIs				Extensive list of side effects ³⁷ ¶
Citalopram	30 mg	No	No benefit over placebo ³³	
Fluoxetine	20 mg	Mixed	Improvement of 24% over placebo among breast cancer survivors ³⁴	
	30 mg		No benefit among women without breast cancer ³³	
Paroxetine	10 to 20 mg	Yes	Improvement of 30% over placebo among breast cancer survivors ³⁵	
	12.5 to 25 mg CR		Improvement of 25% over placebo among women without breast cance	r ³⁶
Sertraline		No	No benefit over placebo among breast cancer survivors ³⁸	
SNRIS				
Venlafaxine	75 or 150 mg	Mixed	Improvement of 34% over placebo among breast cancer survivors ³⁹	Same side effects as for SSRIs, but mini- mal effect on cytochrome P-450 en-
	75 mg ER		No benefit over placebo among women without breast cancer ⁴⁰	zymes (only slightly inhibits conver- sion of tamoxifen to active metabo- lites) ⁴¹ ; possible hypertension
Gabapentin	300 mg 3 times daily	Yes	Improvement of 31% over placebo among breast cancer survivors ⁴² and 23% over placebo among women without breast cancer ⁴³	Nausea, vomiting, somnolence, dizziness, rash, ataxia, fatigue, and leukopenia
Alpha-blockers				Dry mouth, drowsiness, dizziness, hypo-
Clonidine	0.1 mg trans- dermal	Mixed	Little or no benefit ^{4,44} or improvement of 27% over placebo ⁴⁵	tension, and rebound hypertension
Methyldopa	375 to 1125 mg daily in divided doses	No	No benefit over placebo ⁴	

Deborah et al. N Engl J Med 2006;355:2338-47.

Vasomotor Symptoms

Trials in perimenopausal women

- Prospective observational study
 - 30µg EE of OC
 - after >2M, 90% patients complete relief (1985, Shargil, Int J Fertil)
- Randomized, double-blind,
 - 20µg EE + norethindrone acetate 1mg
 - Severe Sx. reduced (50%)

(1997, Casper et al, Menopause)

Sx. may occur during hormone free days.



Irregular or heavy menstrual bleeding

- Premenopausal women with AUB, over age 45
 - EM pathology risk increased
 - OR 3.1 (95% CI, 1.5-6.1)

(1999, Farquhar et al, AJOG)

Table I. Independent risk factors for endometrial hyperplasia and carcinoma in women with abnormal bleeding (N = 1033)

	All abnormal histolog	gic findings	Complex, atypia, and carcinoma only		
Risk factor	Odds ratio and 95% confidence interval	Statistical significance	Odds ratio and 95% confidence interval	Statistical significance	
Weight ≥90 kg	5.5 (2.9-10.6)	<i>P</i> < .0001	7.3 (3.2-16.8)	<i>P</i> < .0001	
Family history of colon cancer	5.0 (1.3-19.1)	<i>P</i> = .0182	9.1 (2.2-37.1)	P = .002	
Infertility	3.6 (1.3-9.9)	<i>P</i> = .0127	3.3 (0.99-11.1)	P = .051	
Age ≥45 y	3.1 (1.5-6.1)	P = .0016	NS	NS	
Nulliparity	2.8 (1.1-7.2)	P = .0267	3.7 (1.2-10.9)	<i>P</i> = .0193	
Family history of endometrial cancer	NS	NS	5.8 (1.1-28.6)	<i>P</i> = .0392	

- Low dose OC recommended
- Prophylaxis against irregular, heavy anovulatory bleeding and the risk of endometrial hyperplasia and neoplasia
- ② Traditional postmenopausal hormone regimen without a contraceptive dose of progestin for the women not amenorrheic or without menopausal sx.
 - Exposing EM to excessively high levels of estrogen
 → risk of endometrial hyperplasia and neoplasia ↑
 Impossible to inhibit ovulation and contraception
 → unexpected pregnancy

ACOG Practice Bulletin

Combination OC is safe in healthy, nonsmoking.

- No increased risk of MI, stroke, breast cancer
- Positive effect on BMD
- Reduction of vasomotor symptoms
- Combination OC could be option for PM.

Risk of VTE, CVD

- Caution with obese, other CV disease
- Should be individualized

(2006, Obstet Gynecol)



Lowest estrogen dose OC available:
 4-fold greater than the standard postMP dose
 Dose-related risks with estrogen significant with increasing age



When to change from OC to postmenopausal HRT??

Treatment free-week method

- annual measure the FSH level, beginning at age 50 (on day 6 or 7 of the estrogen-progestin-free week in a standard 3-week regimen)
- ② FSH >20IU/L → change OC to HRT

Empirical method :

 Empirically switching low dose estrogen-progestin contraception to postmenopausal HRT on midfifties

> Cochrane database review,2005


A progestin-containing intrauterine device (IUD) is another option that offers both control over bleeding and contraception

- Levonorgestrel IUS
- Heavy vaginal bleeding
 Similar effect & less side effect than oral progestin
- Tx of Endometrial hyperplasia
 Similar and probably better effect than standard treatment with oral progestin

Osteoporosis

Across menopause, sigmoid pattern of bone loss
 Begins 2-3yrs before MP, ends 3-4yrs after MP


(J Bone & mineral Res., 2000)








> WHI study, (2002 & 2004)



The first trial with definite data supporting the ability of postmenopausal hormone to prevent fracture at the hip, vertebrae, and other sites.

BMD & Fracture





OC decreased hip fracture

OC preserve BMD.

 Longer duration, greater effect on BMD (Kritz-Silverstein 1993 Am J Public Health; Gambaccinani 1994 Maturitas)

Table I. Decreased hip fracture risk with oral contraceptive use

Age at oral contraceptive use	Multivariate any oral contraceptive	Odds ratio (95% confidence interval) ≥50µg ethinyl estradiol oral contraceptive
Never used	1.0 (referent)	1.0 (referent)
<30 y	1.3 (0.8-2.1)	1.1 (0.6-2.0)
30-39 y	0.8 (0.6-1.2)	0.8 (0.5-1.1)
≥40 y	0.7 (0.5-0.9)	0.6 (0.4-0.9)



Timing hypothesis

0.18	0.24	
0.43	0.39	
0.78	0.62	
	0.43	0.43 0.39

Early Good, Late Bad? Then, when to start HT?

When to start HT?

When is early early enough?
 Late menopausal transition
 (time of accelerated atherosclerosis progression and endothelial dysfunction d/t Estrogen depletion)

For menopausal sx control during menopausal transition : HRT > non hormonal drug

Thomas et al. Menopause: The Journal of The North American Menopause Society 2013;Vol. 20, No. 3, pp. 342/353

Recommendations

 Expert Panel on Menopause in Asian Women
 Initiation during menopausal transition, greatest benefits (2006, Climacteric)

NAMS Position Statement

 No specific recommendation confined to perimenopause
 HT initiation (proximal to MP) may be important. (2010, Menopause)

The Endocrine Society

 No specific recommendation confined to perimenopause
 Menopausal women ages 50 to 59yr, benefits outweigh risks. (2010, JCEM)



International Menopause Society Maturitas 2008

Initiation : for relief of menopausal sx

Treatment by type of symptom during perimenopause

Menstrual disturbance : main symptom
 Progestogens during second half of cycle
 or LNG-IUS

- If vasomotor symptom develop Sequential HRT or Estrogen + LNG-IUS
- Contraception and/or cycle control Low-dose oral contraceptive



International Menopause Society Maturitas 2008

During menopausal transition

- Sequential preparations
 - Relief from vasomotor symtoms
 - Achieve regular withdrawal bleeding
 - Sequential HRT or OC
- Usually after a minimum 1yr of last spontaneous menstruation period
 - bleed-free continuous combined estrogen/progestogen

